SCHEMBL6738879

SCHEMBL6738879

O=C1CSC(=S)N1Cc1ccccc1C(F)(F)F

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3A P49840 6/20 0.58
GSK3B P49841 6/20 0.58
PIM1 P11309 1/20 0.49
ALDH1A1 P00352 7/20 0.48
TDP1 Q9NUW8 5/20 0.48
KMT2A Q03164 4/20 0.48
MEN1 O00255 3/20 0.48
GAA P10253 3/20 0.48
RECQL P46063 3/20 0.48
MAPT P10636 2/20 0.48
THRB P10828 2/20 0.48
HTT P42858 2/20 0.48
LMNA P02545 1/20 0.48
TP53 P04637 1/20 0.48
ALOX15 P16050 1/20 0.48
MAPK1 P28482 1/20 0.48
HSD17B10 Q99714 1/20 0.48
POLB P06746 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
CHRM5 P08912 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13150780 0.81 ALDH1A1 (0.70) GSK3BPIM1ALDH1A1TDP1KMT2A
SCHEMBL20339802 0.78 GSK3B (0.63) GSK3AGSK3BPIM1ALDH1A1TDP1
SCHEMBL20339669 0.78 GSK3A (0.68) GSK3AGSK3BPIM1ALDH1A1TDP1
SCHEMBL20339364 0.75 GSK3A (0.59) GSK3AGSK3BPIM1ALDH1A1TDP1
SCHEMBL3723533 0.74 ALDH1A1 (0.43) PIM1ALDH1A1TDP1KMT2ARECQL
SCHEMBL5468543 0.74 GSK3A (0.66) GSK3AGSK3BALDH1A1TDP1KMT2A
SCHEMBL20339642 0.73 GSK3A (0.56) GSK3AGSK3BPIM1ALDH1A1TDP1
SCHEMBL3176824 0.72 PTGS1 (0.56) GSK3AGSK3BALDH1A1TDP1KMT2A
SCHEMBL11100770 0.71 CA12 (0.58) ALDH1A1TDP1KMT2AMEN1GAA
SCHEMBL1519904 0.70 GSK3A (0.56) GSK3AGSK3BALDH1A1TDP1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040002526-A1 Phospholipase D inhibitors and uses thereof CELL THERAPEUTICS, INC. 2004-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002526-A1 Phospholipase D inhibitors and uses thereof PLD2, PLD1, PLA2G2D GSK3A 2436/4885GSK3B 2077/4885PIM1 2212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.